Slide 1: The First Fully Integrated Functional Medicine Company
The First Fully Integrated Functional Medicine Company Cellular and Regenerative Therapeutics September 2024 v.1.1.0
Slide 2: Legal Disclaimers
LEGAL DISCLAIMERS All statements in this presentation other than statements of historical facts regarding Celularity Inc. (“Celularity”) are “forward-looking statements” reflecting management’s current beliefs and expectations, including those relating to future events. In some cases, you can identi
Slide 3: Fully Integrated Functional Medicine Company
Marketing 6 commercial stage products in regenerative medicine. On track for $50-56MM revenue in 2024. The First On track for three 510(k) filings in FULLY INTEGRATED 2025-2026. FUNCTIONAL MEDICINE Phase II cell therapy data in COMPANY autoimmune and degenerative diseases. State-of-the-art research,
Slide 4: Building on Two+ Decades of Innovation
BUILDING ON TWO+ DECADES OF INNOVATION PATIENTS $100 MILLION CUMULATIVE SECURE RAW STATE OF THE TREATED WITH WORLDWIDE REVENUE MATERIAL ART GMP OUR PATENTS IN SUPPLY CHAIN GENERATED ADVANCED AND R&D PORTFOLIO DONORS SINCE 2018 BIOMATERIAL FACILITY BIOBANKED SPIN-OUT PRODUCTS ~ $120MM > 45,000 > 250,
Slide 5: Growth Drivers and Revenue
HIGHLY INTEGRATED INDUSTRIALIZED BUSINESS MODEL ADVANCED BIOBANKING CELL BIOMATERIALS SERVICES THERAPY • Controlled raw material REVENUE DRIVERS • A suite of commercial products supply chain • CDMO for autologous / allogeneic cell therapy • Out-license partnership • Lifebank® newborn stem products w
Slide 6: Current Commercial Biomaterial Products
CURRENT COMMERCIAL BIOMATERIAL PRODUCTS Completely Connective tissue Completely Designed for Completely Completely decellularized matrix (CTM) from decellularized ocular surface decellularized decellularized placenta-derived chorionic plate of placenta-derived diseases and human placental Full Thick
Slide 7: Value Drivers and Commercial Opportunities
Growing brand visibility opening new market opportunities. >70% operating margins on current commercial products. NEAR-TERM Revenue growth creates pathway VALUE DRIVERS AND to profitability in 12-15 months. COMMERCIAL OPPORTUNITIES Compelling Phase II human clinical cell therapy data in autoimmune/d
Slide 8: Next Generation Advanced Biomaterial Pipeline Highlights
NEXT GENERATION ADVANCED BIOMATERIAL PIPELINE HIGHLIGHTS Unparalelled manufacturing capabilities and development expertise Pipeline Products CELULARITY FUSE BONE CELULARITY TENDON VOID FILLER PLACENTAL WRAP (CTW) (FUSE) MATRIX (CPM) TENDON MANAGEMENT ORTHOPEDICS/BONE WOUND MANAGEMENT/AESTHETICS • Su
Slide 9: Sizable Untapped Opportunities in Wound, Orthopedics, Aesthetic Markets
INNOVATING FOR CONSISTENT REVENUE GROWTH On track for three 510(k) filings in 2025-2026 Pre- Q- 510(k) 510(k) Development Studies RFD1 Sub2 Submission3 Progress Celularity Tendon Wrap ✓ ✓ ✓ 80% H1 2025 Fuse Bone Void Filler ✓ ✓ ✓ 60% H2 2025 Celularity Placental Matrix ✓ ✓ 50% H2 2026 1Pre-Request f
Slide 10: Deep Manufacturing Expertise
DEEP MANUFACTURING EXPERTISE Fully Integrated, Purpose-Built Commercial Scale Manufacturing Site Including Translational Research & Biorepository Purpose Built Facility for Commercial-scale Cellular Therapeutic Manufacturing ▪ $100M investment in cGMP/cGTP manufacturing ▪ Enables greater control, ef
Slide 11: Disruptive Value Opportunity in Longevity and Human Performance
The only company with 3 clinical stage assets applicable to longevity and preservation of human performance. Robust regenerative medicine product pipeline. 3-5 YEAR Multiple partnership-ready clinical DISRUPTIVE VALUE stage assets in cell therapy. OPPORTUNITY Human clinical stage placental IN LONGEV
Slide 12: Cellular Senescence Drives Aging-Related Pathologies
CELLULAR SENESCENCE DRIVES AGING-RELATED PATHOLOGIES Senescence involves cell-cycle arrest and the release of inflammatory cytokines. Senescent cells promote a state known as ‘inflammaging’. Persistence of senescent cells are maladaptive, driving inflammatory diseases and cancer. Early clinical data
Slide 13: Rationale for Placental NK Cells as a Senoablatant
RATIONALE FOR PLACENTAL NK CELLS AS A SENOABLATANT Clinical Candidates Procurement CD34 Cell Isolation Feeder-free, Cytokine Cocktail-driven Expansion/Differentiation Process CYNK-001 Unmodified Lymphocytic CD34 cells CYNK Cells Progenitors Cryopreserved CD34+ Bank Donor CYNK-201 CD16+IL-15 Freeze f
Slide 14: CYNK-001: A Clinical Stage Candidate
CYNK-001: A CLINICAL STAGE CANDIDATE • Celularity has dosed 46 subjects with CYNK-001 (IV) within various indications. • Overall safety of CYNK-001 was well-tolerated with transient Grade 1 or 2 cytokine release syndrome (CRS) attributed to the product. Total No. of SUBJECTS CYNK-001 150 million on
Slide 15: Placental NK Cells Exhibit Activity Against Senescent Cells In Vitro
PLACENTAL NK CELLS EXHIBIT ACTIVITY AGAINST SENESCENT CELLS IN VITRO CYNK-001 and CYNK-201 cells demonstrated significantly enhanced elimination of senescent cells in pre-clinical studies Chemo-induced Senescence Cytokine β-Gal expression Cytotoxicity response CONFIDENTIAL Page 15
Slide 16: Opportunities in Age-Related Diseases
Opportunities in Age-Related Diseases TARGETING THE COMMON BIOLOGY OF CANCER AND AGE-RELATED DISEASES
Slide 17: Age-Related Sarcopenia
AGE-RELATED SARCOPENIA o Age-related loss of skeletal muscle mass and function. GLP-1 mediated muscle loss may be a target. o The prevalence in 60–70 age is reported as 5–13%, while the prevalence ranges from 11 to 50% in people >80 years. Global population aged ≥60 years is expected to rise to 1.2
Slide 18: Age-Related Frailty
AGE-RELATED FRAILTY • Increased serum levels of inflammatory molecules, including CRP (C-reactive protein), IL-6 (interleukin 6) and sTNF-RII (75 kDa soluble TNFα receptor II), have been observed in frail and pre-frail elderly people. • Fried Frailty Index: weight loss, exhaustion, low physical acti
Slide 19: Age-Related Immunosenescence
AGE-RELATED IMMUNOSENESCENCE • Age-related impairment of immune function (immunosenescence) increases morbidity and mortality in infectious diseases, i.e. COVID-19. • Senescent cells can secrete pro-inflammatory cytokines, chemokines, and extracellular matrix protease, termed the senescence-associat
Slide 20: Uniquely Positioned to Be a Dominating Company in Longevity and Human Performance
U N I Q U E LY P O S I T I O N E D T O B E A D O M I N AT I N G C O M PA N Y I N L O N G E V I T Y A N D HUMAN PERFORMANCE A Healthcare Challenge: The Impending Silver Tsunami A perfect storm is brewing in the healthcare sector, driven by several interconnected factors: The Rapidly Expanding Aging P
Slide 21: The Addressable Market for Scalable Therapeutic Solutions in Longevity
THE ADDRESSABLE MARKET FOR SCALABLE THERAPEUTIC SOLUTIONS IN LONGEVITY IS UNPRECEDENTED The ROI for longevity-based interventions which increase the relative proportion of wealth accumulation years in the population over 65 justifies the expense to government and/or private payers. Target market is
Slide 22: Summary
Marketing 6 commercial stage products in regenerative medicine. On track for $50-56MM revenue in 2024. On track for three 510(k) filings in SUMMARY 2025-2026. Phase II cell therapy data in autoimmune and degenerative diseases. Opportunities in age- related diseases/longevity. State-of-the-art resear